開拓藥業(09939.HK)計劃於明年上半年提交普克魯胺之新藥申請
開拓藥業(09939.HK)公布,公司正在中國開展多中心、隨機、雙盲、安慰劑對照的臨床試驗,評估普克魯胺對進行阿比特龍及多西他賽治療後或對其不耐受的轉移性去勢抵抗性前列腺癌(mCRPC)患者的療效及安全性,已考慮來自獨立數據監查委員會的建議,公司將繼續進行III期臨床試驗,並計劃於2021年上半年根據第二個主要終點(OS)的最終分析向國家藥監局提交普克魯胺的NDA申請。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.